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Aims: Relatively little is known about the use of medication for the secondary prevention of cardiovascular dis-
ease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors.
Methods and results:We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults
aged 30–79 years recruited from 1737 rural and urban communities in China. Information about doctor-
diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention
of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios
(ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Over-
all, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported cur-
rent use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I,β-blockers or calcium-channel blockers)
for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income,
education, BMI or blood pressure. The use of these agentswas associated positivelywith history of diagnosed hy-
pertension (OR 7.5; 95% conﬁdence intervals: 7.08–8.06) and diabetes (1.40; 1.28–1.52) and inversely with self-
rated health status, but there was no association with years since diagnosis.
Conclusions: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD
was routinely treatedwith any proven secondary preventive drugs. The treatment rateswere correlatedwith the
existence of other risk factors, in particular evidence of hypertension.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Worldwide, about 17 million people die from cardiovascular disease
(CVD) each year, chieﬂy from ischemic heart disease (IHD) and stroke,
with about three-quarters of these deaths now occurring in low- org, Old RoadCampus, University
1865 743984.
king University Health Science
, lmlee@vip.163.com (L. Li).
land Ltd.Open access under CC BY-NCmiddle-income countries, including China [1–3]. InmostWestern coun-
tries, the mortality rates from CVD have declined progressively in the
last few decades, due partly to widespread and long-term use of proven
medication, such as antiplatelet therapy, statins, β-blockers and ACE-
inhibitors (ACE-I), for the secondary prevention of CVD events, and
partly due to favourable changes in underlying risk factors, such as
smoking and dietary patterns [4–9]. Although the acute hospital man-
agement of patients with CVD in China is generally similar to that in
most Western countries [10], relatively little is known about the use of
drug treatment for secondary prevention of CVD events in the commu-
nity in China. We examined cross-sectional data about the use of med-
ication for secondary prevention of CVD (which is deﬁned as IHD and
or stroke throughout this paper) among adults who were recruited in
the China Kadoorie Biobank (CKB) Study from over 1737 rural and-ND license. 
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to examine the use of six speciﬁc classes of drug treatment for second-
ary prevention of CVD and relevance to it of a range of demographic, so-
cioeconomic, lifestyle and health-related factors.2. Methods
2.1. Study participants
The present study population consisted of 23 129 participants in the CKBwho report-
ed having a history of doctor-diagnosed IHD and/or stroke (including transient ischemic
attack [TIA]) at the baseline survey. Details of the design, survey methods and baseline
characteristics of the CKB participants have been reported previously [11,12]. In brief,
the CKB study involved 512 891 people who were recruited during 2004–8 from 1737
communities in 10 geographically diverse regions (5 urban and 5 rural) of China, chosen
according to local disease patterns, exposure to certain risk factors, population stability,
quality of death and disease registries, local commitment and capacity. In each region,
all men and women aged 35–74 years were identiﬁed through ofﬁcial residential recordsTable 1
Selected baseline characteristics of study participants, by history of IHD, stroke and either or b
All (n = 512891) History of IHD
(n = 15 472)
No. No.
Age (years)
b50 230553 1510
50–59 157556 4502
60–69 91771 6416
70–79 33011 3044
Mean (SD) 61.4 (8.7)
Gender
Male 210222 5714
Female 302669 9758
Region
Rural 286705 4963
Urban 226186 10509
Education
No formal school 95221 2399
Primary school 165216 4958
Middle school 144913 3804
High school 77527 2645
College/university 30014 1666
Household income (Yuan/year)
b4999 50203 1232
5000–9999 94629 2263
10000–19999 149013 5099
20000–34999 126721 4101
35000+ 92325 2777
Cigarette smoking
Never 317614 10079
Ex 30563 1901
Current 164714 3492
Alcohol drinking
Never 235199 7853
Ex 9256 647
Current 268436 6972
SBP (mm Hg)
b120 163260 3046
120–139 201619 5578
140–159 96713 4185
160+ 51299 2663
Mean (SD) 140.0 (22.6)
BMI (kg/m2)
b22.0 168547 3000
22.0–24.9 175414 4660
25.0–26.9 85856 3255
27+ 83074 4557
Mean (SD) 25.1 (3.7)
Self-reported hypertension 59703 6749
Self-reported diabetes 16162 2053
Self-rated poor health status 53105 4297
Short of breath during walking 30351 3341
a Adjusted for age, gender, region and education except when the variable is in question.and invited to attend study clinics set up speciﬁcally in local residential community cen-
tres (with a small number slightly outside of this age range when recruited).2.2. Data collection
The baseline survey included a face-to-face interview by trained study staff with a
laptop-administrated questionnaire, physical examination (e.g., height, weight, blood
pressure, heart rate and lung function) and collection of blood for storage and future anal-
ysis. At the interview, apart from a range of questions related to demographic and lifestyle
factors (e.g., smoking, alcohol, diet and physical activity) a detailed medical history was
sought from participants, with the question: “Has a doctor EVER told you that you had the
following disease?” followed by a list of about 20 major conditions, including IHD and
stroke. If a study participant had a prior history of IHD and/or stroke, they were then
asked about the age of ﬁrst diagnosis and whether they were currently taking any drug
treatment, and if so, whether this included any of six speciﬁc classes of drug (anti-platelet,
statins, diuretics, ACE-I, β-blockers and calcium-channel blockers) that are used for the
secondary prevention of CVD events. To facilitate the recording of drugs that were used
a detailed list of possible drug names (including generic and commercial names) for
each of these six classes of drug was provided to participants. All participants providedoth.
History of stroke
(n = 8884)
History of either or both
(n = 23129)
(%)a No. (%)a No. (%)a
(0.6) 798 (0.4) 2277 (1.0)
(3.0) 2690 (1.8) 6938 (4.6)
(7.0) 3664 (4.0) 9481 (10.4)
(8.6) 1732 (4.6) 4433 (12.5)
61.5 (8.4) 61.2 (8.6)
(2.5) 4912 (2.2) 10069 (4.5)
(3.4) 3972 (1.4) 13060 (4.5)
(2.8) 3615 (1.2) 8347 (3.8)
(3.3) 5269 (2.4) 14782 (5.3)
(2.3) 1518 (1.7) 3758 (3.7)
(2.9) 3053 (1.8) 7689 (4.5)
(3.2) 2322 (1.8) 5783 (4.7)
(3.7) 1292 (1.6) 3712 (5.0)
(3.9) 699 (1.3) 2187 (4.9)
(2.6) 1133 (2.0) 2272 (4.4)
(2.8) 1505 (1.9) 3630 (4.5)
(3.0) 2937 (1.8) 7625 (4.5)
(3.1) 2026 (1.6) 5781 (4.5)
(3.4) 1283 (1.5) 3821 (4.7)
(3.1) 4458 (1.7) 13845 (4.5)
(4.4) 1612 (2.9) 3274 (7.1)
(2.7) 2814 (1.6) 6010 (4.0)
(3.4) 4024 (2.2) 11270 (5.4)
(6.6) 754 (6.3) 1317 (13.1)
(2.5) 4106 (1.2) 10542 (3.5)
(2.5) 1065 (0.9) 3950 (3.2)
(3.1) 2851 (1.6) 8050 (4.5)
(3.5) 2731 (2.4) 6517 (5.6)
(3.7) 2237 (3.5) 4612 (6.8)
145.5 (23.6) 141.2 (23.1)
(2.0) 1901 (1.2) 4720 (3.1)
(2.9) 2953 (1.8) 7240 (4.4)
(3.6) 1853 (2.1) 4846 (5.4)
(4.6) 2177 (2.4) 6323 (6.7)
24.7 (3.4) 24.9 (3.6)
(8.6) 5212 (7.6) 11141 (15.7)
(6.9) 1107 (4.0) 2849 (10.3)
(8.4) 3300 (6.2) 7028 (14.1)
(10.8) 1274 (3.9) 4305 (14.1)
90 Y. Chen et al. / International Journal of Cardiology 172 (2014) 88–95written informed consent to take part in the CKB study. Ethics approvals were obtained
from Central Ethical Committee of the Chinese Centre for Disease Control and Prevention
(CDC), Beijing, China, and the University of OxfordUK, aswell as from the Institutional Re-
search Boards in the 10 study regions.2.3. Statistical analysis
The proportions of participants with prior CVDwhowere using the six classes of drug
were calculated separately for participants who had either IHD or stroke, or both, and
were adjusted for age, gender, geographical region and education.Multivariate logistic re-
gression models were used to estimate rates of use of these drugs, calculate odds ratios
(OR) and 95% conﬁdence intervals (CIs) among participants with prior CVD both overall
and for IHD or stroke, in different categories of baseline variables (including CVD risk fac-
tors). Odds ratio (and 95% CI) of use of six proven CVD medications by levels of systolic
blood pressure (SBP) were estimated for each group relative to the lowest and are
shown as “ﬂoating absolute risks” (which does not alter their values but merely ascribes
a 95% conﬁdence interval [CI] to the RR in every group) [13]. All analyses were conducted
using SAS version 9.2 (SAS institute Inc., Cary, North Carolina, USA).3. Results
3.1. Characteristics of the study population
Overall, 23 129 (4.5%) of the CKB participants reported a prior histo-
ry of CVD, including 15 472 (3.0%) with IHD and 8884 (1.7%) with
stroke (Table 1). The prevalence of IHD was higher in women (3.4%)
than in men (2.5%) and, consistently, also in those with higher levels
of education or of household income (Table 1). For stroke, the preva-
lence was higher in men (2.2%) than women (1.4%) and, in contrast to
IHD, in thosewith lower levels of education and income. The prevalence
of IHD and stroke were both strongly and positively associated with in-
creasing levels of systolic blood pressure and body mass index (BMI)
(Table 1). Participants who had poor self-rated health status had a
higher prevalence of either IHD or stroke (14.1%) compared with
those who had good self-rated health status (2.0%).3.2. Use of proven drug therapy in participants with prior CVD
Among participants with a prior history of CVD (IHD and/or stroke),
the median interval since diagnosis was 5.0 (IQR 2.0–10.0) years and
about half of them (55.5%) reported current use of any drug treatment,
but only about one-third (35.3%) reported current use of any of the six
proven categories of drug treatment for CVD event prevention
(Table 2). Among these six drug categories, the reported current
use were 1.4% for statins, 2.3% for diuretics, 7.6% for ACE-I, 10.1% for
β-blockers, 10.6% for anti-platelet (chieﬂy aspirin) and 18.2% for
calcium channel blockers. Only 9% of these high-risk patients reported
concurrent use of two of these drug categories and 2.7% reported con-
current use of three or more. There was little difference in the propor-
tions having individual or combined use of such treatments between
those with IHD and stroke.Table 2
Use of any secondary prevention drug treatment among participants with a prior history of IH
IHD (n = 15472)
No. (%)
Any treatment 8739 (56.4)
Any of six drugs 5382 (34.8)
Calcium channel blockers 2722 (17.6)
β-Blockers 1903 (12.3)
ACE-I 1045 (6.8)
Diuretics 351 (2.3)
Anti-platelet 1557 (10.1)
Statins 215 (1.4)
Year since diagnosis
Median (IQR)
6.5 (2.5–11.5)3.3. Correlate of use of secondary prevention treatments for CVD
Table 3 shows the OR (and 95% CI) for use of any of the six proven
drug treatment categories by demographic factors (age, gender and re-
gion) and socioeconomic status (education level, annual household in-
come) among people with prior CVD adjusted for age, gender, region
and education except that when the variable is in question. For IHD,
all else being equal, there was lower usage among younger people
(e.g., OR 0.44; 95% CI: 0.39–0.50 for b50 years versus 70+ years), in
women (0.87; 0.80–0.93), and in those living in urban areas (0.78;
0.72–0.85). Less education was associated strongly with less use of
any of the six established drug treatments, and of each speciﬁc drug cat-
egory, for both IHD (Fig. 1, left) and stroke (Fig. 1, right). By contrast, an-
nual household incomewas positively associated with use of any of the
six drug treatments (Table 3).
Table 4 shows the adjusted ORs for use of any of the six classes of
drug by alcohol, smoking, SBP, hypertension, BMI, and diabetesmellitus
(DM). Usage rates were moderately lower in current smokers (0.84;
0.79–0.89) and current drinkers (0.76; 0.73–0.79), but strongly posi-
tively associated with measured BMI and SBP (p for trend b 0.0001).
For every 10 mm Hg higher baseline SBP, the use of these treatments
was 16.5% higher (p b 0.0001; Fig. 2). Moreover, individuals with self-
reported hypertension were almost 8 fold (7.55; 7.08–8.06) as likely
to report use of such therapy as those without such a diagnosis, not
only for agents with BP-lowering effects (40.7% vs 12.0%) but also for
statins (2.1% vs 0.8%) and aspirin (15.4% vs 5.9%) (Fig. 3, left). The pat-
tern was similar for participants with a history of stroke (Fig. 3, right).
This would leave 56% of IHD patients and 41% of stroke patients in the
present study that had not been diagnosed previously with hyperten-
sion under-treated despite a high risk of recurrence of IHD or stroke.
Higher use of these six drugs also was associated with prior history of
DM (1.40; 1.48–1.52) and the pattern was similar for participants
with a history of stroke and/or IHD. Years of diagnosis has no signiﬁcant
effect in the use of the six drugs among participants with a history of ei-
ther IHDor stroke (Table 4). Health status self-rated as goodwas strong-
ly associated with lower use of the six drugs in individuals with prior
IHD (0.52; 0.48–0.57) or stroke (0.58; 0.52–0.65).4. Discussion
This is the largest community-based study carried out in China on
the use of drug therapy for secondary prevention in people with prior
IHD and stroke. It shows that only about one-third of patients with
CVD in the community were taking any proven medication for second-
ary prevention of CVD events. The use of 6 proven drug treatments for
secondary prevention of CVDwas unrelated to the years since diagnosis,
but associated with a number of socio-economic (especially low educa-
tion), lifestyle (e.g., smoking, alcohol drinking) and physiological factors
(e.g., BMI and blood pressure). The effect of blood pressure on the use of
treatment was particularly striking, and those reporting having aD, stroke and either or both at baseline.
Stroke (n = 8884) Either or both (n = 23129)
No. (%) No. (%)
4598 (51.8) 12841 (55.5)
3396 (38.2) 8156 (35.3)
1824 (20.5) 4211 (18.2)
634 (7.1) 2341 (10.1)
857 (9.6) 1761 (7.6)
246 (2.8) 536 (2.3)
1098 (12.4) 2447 (10.6)
137 (1.5) 319 (1.4)
4.5 (1.5–8.5) 5.0 (2.0–10.0)
Table 3
Use of any secondary prevention drug treatment among participants with a prior history of IHD, stroke and either or both at baseline by demographic and socioeconomic characteristics.
Baseline measure IHD (n = 15 472) Stroke (n = 8 884) Either or both (n = 23 129)
No. %a OR (95% CI)a No. %a OR (95% CI)a No. %a OR (95% CI)a
Age group (years)
b50 362 22.6 0.44 (0.39–0.50) 306 34.6 0.81 (0.69–0.94) 652 26.3 0.56 (0.51–0.62)
50–59 1471 31.7 0.71 (0.66–0.75) 1 057 37.7 0.92 (0.85–1.00) 2 397 33.3 0.78 (0.75–0.82)
60–69 2395 37.5 0.91 (0.87–0.96) 1 407 38.7 0.96 (0.90–1.03) 3 496 37.1 0.93 (0.89–0.97)
70+ 1154 39.6 1.00 (0.92–1.09) 626 39.7 1.00 (0.90–1.11) 1 611 38.9 1.00 (0.93–1.07)
P (Trend) b0.0001 0.14 b0.0001
Gender
Male 2207 36.8 1.00 1 913 37.4 1.00 3 823 36.3 1.00
Female 3175 33.6 0.87 (0.80–0.93) 1 483 39.2 1.08 (0.98–1.19) 4 333 34.4 0.92 (0.87–0.98)
P (Heterogeneity) b0.0001 0.11 b0.01
Region
Rural 1807 38.6 1.00 1 607 46.8 1.00 3 264 41.3 1.00
Urban 3575 33.0 0.78 (0.72–0.85) 1 789 32.4 0.54 (0.49–0.60) 4 892 31.9 0.67 (0.62–0.71)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
Education level
No formal 684 26.6 1.00 (0.90–1.11) 471 27.3 1.00 (0.87–1.15) 1 080 26.0 1.00 (0.92–1.09)
Primary 1830 33.7 1.40 (1.32–1.50) 1 242 36.1 1.51 (1.39–1.63) 2 887 33.8 1.45 (1.38–1.53)
Middle 1335 37.1 1.63 (1.52–1.74) 895 41.2 1.87 (1.71–2.04) 2 069 38.0 1.74 (1.65–1.84)
High 974 39.7 1.82 (1.68–1.98) 527 46.1 2.28 (2.02–2.56) 1 389 41.2 1.99 (1.86–2.14)
College/university 559 36.6 1.59 (1.43–1.78) 261 46.7 2.33 (1.98–2.75) 731 38.8 1.80 (1.64–1.99)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
Household income (Yuan/year)
b4999 361 27.7 1.00 (0.87–1.14) 415 34.5 1.00 (0.87–1.15) 735 30.2 1.00 (0.91–1.10)
5000–9999 744 32.6 1.26 (1.15–1.38) 601 38.0 1.16 (1.04–1.30) 1 276 34.3 1.21 (1.12–1.30)
10000–19999 1826 35.7 1.45 (1.36–1.53) 1 091 37.5 1.14 (1.05–1.23) 2 700 35.4 1.27 (1.21–1.33)
20000–34999 1457 35.5 1.44 (1.34–1.54) 793 40.2 1.28 (1.16–1.41) 2 071 36.2 1.31 (1.24–1.39)
35000+ 994 36.9 1.53 (1.39–1.67) 496 40.5 1.29 (1.13–1.47) 1 374 37.4 1.38 (1.28–1.49)
P (Trend) b0.0001 0.05 b0.0001
a Adjusted for age, gender, region and education except when the variable is in question.
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use of such treatment as those without such a diagnosis.
Although the reported use of various treatments for secondary pre-
vention of IHD and stroke in the present study was generally lower
than that reported in clinical settings from particular Chinese cities
[14,15], our study ﬁndings are broadly consistent with the results of
the PURE study [1] among 46 285 participants, aged 35–70 years re-
cruited during 2004–9 from 115 urban and rural communities across
China (in addition to participants from 16 other countries). In that
study, 3070 (6.6%) of the Chinese participants reported having a history0
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Fig. 1. Percentage use of six proven CVD medication categories by level of education in paof IHD (5.2%) or stroke (1.9%) and, among them, 18.6%, 6.2%, 8.6%, 14.3%,
14.9% and 1.7%, reported taking antiplatelet drug, β-blockers, ACE-I, di-
uretics, calcium-channel blockers and statins [1] compared with 10.6%,
10.1%, 7.6%, 2.3%,18.2% and 1.4% respectively in the present study. In
both the PURE-China study and CKB, the use of anti-platelet agents
(18.6% and 10.6%) and any of the BP-lowering drugs (38.2% and
34.4%) for participants with a history of either IHD or stroke in China
was much lower than participants in the PURE study from North
America (antiplatelet drugs: 52.2%, BP-lowering medication: 69.2%),
Middle East (49.7%, 64.3%) and South Americans (29.0%, 57.8%) and0
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rticipants with a history of IHD (left) or stroke (right). Vertical lines indicate 95% CIs.
Table 4
Odds ratios for use of any secondary prevention drug treatment by lifestyle and physical measurements.
IHD
(n = 15472)
(n = 5 382)
Stroke (n = 8 884) Either or both (n = 23129)
No. %a OR (95% CI)a No. %a OR (95% CI)a No. %a OR (95% CI)a
Cigarette smoking
Never 3431 35.8 1.00 (0.92–1.09) 1711 38.6 1.00 (0.89–1.12) 4785 36.0 1.00 (0.93–1.08)
Ex 761 36.9 1.05 (0.95–1.15) 662 42.5 1.17 (1.06–1.30) 1299 38.3 1.11 (1.03–1.19)
Current 1190 30.8 0.80 (0.74–0.86) 1023 35.1 0.86 (0.79–0.93) 2072 32.0 0.84 (0.79–0.89)
P (Trend) b0.0001 b0.0001 b0.0001
Alcohol drinking
Never 2899 40.6 1.00 (0.94–1.06) 1632 39.9 1.00 (0.92–1.08) 4215 37.8 1.00 (0.95–1.05)
Ex 287 30.9 1.13 (0.96–1.33) 351 46.6 1.32 (1.13–1.54) 590 42.9 1.23 (1.10–1.38)
Current 2 196 34.8 0.74 (0.70–0.78) 1413 35.1 0.81 (0.76–0.87) 3351 31.6 0.76 (0.73–0.79)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
SBP (mm Hg)
b120 695 23.3 1.00 (0.92–1.09) 254 23.6 1.00 (0.86–1.16) 888 22.6 1.00 (0.93–1.08)
120–139 1760 31.3 1.50 (1.42–1.59) 972 33.9 1.66 (1.54–1.80) 2560 31.5 1.57 (1.50–1.65)
140–159 1663 39.5 2.16 (2.03–2.30) 1116 41.4 2.29 (2.12–2.48) 2562 39.5 2.23 (2.12–2.35)
160+ 1264 47.9 3.04 (2.80–3.29) 1054 46.9 2.87 (2.62–3.13) 2146 46.8 3.02 (2.84–3.20)
P (Trend) b0.0001 b0.0001 b0.0001
BMI (kg/m2)
b22.0 785 23.2 1.00 (0.92–1.09) 594 27.2 1.00 (0.90–1.11) 1308 24.5 1.00 (0.93–1.07)
22.0–24.9 1626 33.8 1.69 (1.59–1.80) 1097 36.1 1.52 (1.40–1.64) 2541 34.0 1.59 (1.52–1.67)
25.0–26.9 1173 36.4 1.89 (1.76–2.04) 737 41.1 1.87 (1.70–2.06) 1777 37.3 1.84 (1.73–1.95)
27.0+ 1798 42.3 2.42 (2.27–2.59) 968 48.3 2.50 (2.28–2.74) 2530 43.2 2.35 (2.23–2.49)
P (Trend) b0.0001 b0.0001 b0.0001
Years since diagnose
b3 1418 35.0 1.00 (0.94–1.07) 1288 38.6 1.00 (0.93–1.08) 2449 35.3 1.00 (0.95–1.05)
3 to b 7 1518 34.3 0.97 (0.91–1.03) 1147 38.9 1.01 (0.94–1.09) 2448 35.0 0.99 (0.94–1.04)
7 + 2446 35.0 1.00 (0.95–1.06) 961 37 0.93 (0.86–1.01) 3259 35.4 1.01 (0.96–1.06)
P-Trend 0.69 0.29 0.88
Self-reported diabetes
No 4512 33.6 1.00 2914 37.2 1.00 6979 34.3 1.00
Yes 870 42.4 1.45 (1.32–1.60) 482 45.4 1.41 (1.23–1.61) 1177 42.2 1.40 (1.28–1.52)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
Self-reported hypertension
No 1428 15.9 1.00 525 13.7 1.00 1861 15.0 1.00
Yes 3954 59.2 7.69 (7.10–8.31) 2871 55.5 7.88 (7.04–8.82) 6295 57.1 7.55 (7.08–8.06)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
Self-rated health status
Poor 1777 42.2 1.00 (0.94–1.07) 1428 43.1 1.00 (0.93–1.07) 2883 41.3 1.00 (0.95–1.05)
Fair 2744 33.7 0.70 (0.67–0.73) 1498 37.2 0.78 (0.73–0.84) 3992 34.4 0.74 (0.12–0.78)
Good 861 27.5 0.52 (0.48–0.57) 470 30.7 0.58 (0.52–0.65) 1281 28.3 0.56 (0.52–0.56)
P (Heterogeneity) b0.0001 b0.0001 b0.0001
a Adjusted for age, gender, region and education.
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Fig. 2.Odds ratio of use of six proven CVDmedication categories by levels of systolic blood
pressure in participants with a history of cardiovascular disease. Numbers of people with
prior CVD are also given for each group.Odds ratios are plotted on a ﬂoating absolute scale.
Each closed square has an area inversely proportional to the effective variance of the log of
the odds ratio. Vertical lines indicate 95% CIs.
92 Y. Chen et al. / International Journal of Cardiology 172 (2014) 88–95only slightly better than among participants from South Asia (9.3%,
18.8%), Malaysia (13.6%, 23.9%) and Africa (5.7%, 15.9%). In addition,
there was also virtually no long-term use of statins among patients
with IHD and/or stroke in the communities of China (IHD: 2% in
PURE-China and 1.4% in CKB; stroke: 0.8% in both studies) during
2004–2008. These ﬁgures were similar to these for PURE in Africa
(1.4% for IHD; 0% for stroke), but much lower than those observed in
North America and Europe (56.7%; 38.7%).
Several factors could affect the use of drug therapy for secondary
prevention of CVD events after discharge from hospital, including local
treatment guidelines, doctors' knowledge and beliefs, concerns about
adverse effects, uncertainty about diagnosis and disease severity, afford-
ability, patients' awareness of the risks and self-perceived health status.
Firstly, the six proven drugs for secondary prevention of CVD events se-
lected in the present study are all recommended by Chinese guidelines,
not only for IHD [16] but also for ischemic stroke and TIA [17]. Indeed, a
recent nationwide survey in China found that over 95% of doctors across
over 1029 different types of hospitals said that they would prescribe a
statin at discharge for long-term secondary prevention of IHD or stroke
[10]. So, it seems unlikely that the knowledge or beliefs of hospital doc-
tors in Chinawould inﬂuence its long-termuse, even though there is re-
cent evidence that use of higher doses of statins (e.g., simvastatin
N40 mg) would lead to much greater risk of myopathy in Chinese [18]
than in Western populations [19]. On the other hand, the uncertainty
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Fig. 3. Percentage use of six proven CVD medication categories in participants with and without doctor-diagnosed hypertension among those with IHD (left) and stroke (right). Vertical
lines indicate 95% CIs.
93Y. Chen et al. / International Journal of Cardiology 172 (2014) 88–95of diagnosis and disease severity may contribute to the relatively lower
use in urban than in rural areas in the present study, which is opposite
to that seen in the PURE-China study [1].
As in PURE [1], we also found the use of the drug treatment was as-
sociated with socioeconomic status, smoking and alcohol drinking. The
signiﬁcantly lower use of medication among regular smokers or
drinkers may reﬂect the so-called “crowding out effect” [20] where
the costs of smoking and drinking compromised the allocation of ex-
penditure for essential treatment. Although most of the CKB partici-
pants had certain health insurance cover at baseline, no speciﬁc
information was available at baseline about type of health insurance
cover and level of reimbursement. In China, health insurance coverage
has risen rapidly during the last 10 year, from 29.7% in 2003 to N90%
in 2010 [21], but in most rural areas the average reimbursement rate
for outpatient care under the New Rural Cooperative Health Scheme
(NCMS) is only about 10% [22]. As secondary treatments were mostly
prescribed in the outpatient clinic, their use is more likely to be affected
by the price of the drugs and the reimbursement policy. Of the six prov-
en drug treatment categories, statins were the most expensive, costing
for example 2555 RMB (~£270) a year for daily treatment with 20 mg
simvastatin between 2004 and 2008 [23], with little difference in price
between generic and non-generic drugs, which may account for its ex-
tremely low use in the present study population during that period.
Self-rated health status has been recognised as a useful index for use
of health services [24,25] and a predictor for future vascular events and
mortality [25]. The present study is, to our knowledge, the ﬁrst to report
the association between self-rated health status and usage of long-term
medication. Those who self-rated their health status as “poor” were
nearly twice as likely to be on secondary prevention treatments com-
pared with those with “good” health status, suggesting that feeling
good about their health is an important determinant of non-
medication or non-adherence to medication in individuals. It is not
clear in the present study population whether the self-reported health
status is correlated with the severity of the disease diagnosed.
Themost important ﬁnding in the present study is, perhaps, that the
treatment rate in secondary prevention is inﬂuenced strongly by the
awareness of the individual risk factors rather than overall absolute
risk. Many CVD patients even in the “so-called” normal range of distri-
bution of blood pressure and cholesterol are at substantial absolute
risk of developing further cardiovascular events. There is well-
established randomised evidence that blood pressure [26] and lipidlowering treatments confer substantial beneﬁt regardless of pre-
treatment levels of blood pressure or blood cholesterol [27]. On the
other hand, some drug classes that are widely used for blood pressure
lowering treatment (such as β-blocker and ACE-I) have also been
shown to be particularly effective for secondary prevention following
IHD [6,7]. It is not clear whether the treatment pattern observed in
this study reﬂects a lack of understanding by Chinese doctors about
the effects of these treatments, or is driven mainly by reimbursement
policies, or both.
One of the limitations of the present study is that it was not designed
to be nationally representative, so the ﬁndings should be generalized
with caution to the overall Chinese population. Moreover, the diagnosis
of CVD and use of six proven drug categories were based on self-
reporteddatawithout any objective validation.However, both the prev-
alent rates of self- reported IHD and stroke, aswell as the treatment pat-
terns, in the present study were comparable to those reported by the
PURE-China study, in which 89% of the participants with self-reported
IHD and/or stroke had their diagnoses conﬁrmed by central adjudica-
tion [1]. There is also good evidence from many other studies in differ-
ent populations that self-reported IHD and stroke have a high degree
of speciﬁcity [28–32].
In summary this large community-based survey of 1737 rural and
urban communities of China found that only 1 in 3 individuals with a
history of CVD receive any established secondary preventive treat-
ments.While lack of appropriate awareness of perceived risk amongpa-
tients may contribute to substantial under-use of such therapy, several
other factors could also play an important role, including inappropriate
reimbursement policies (e.g., short period of reimbursement for statins
following CVD) which should be addressed.
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